Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.
Krzyzanowska MK, Julian JA, Gu CS, Powis M, Li Q, Enright K, Howell D, Earle CC, Gandhi S, Rask S, Brezden-Masley C, Dent S, Hajra L, Freeman O, Spadafora S, Hamm C, Califaretti N, Trudeau M, Levine MN, Amir E, Bordeleau L, Chiarotto JA, Elser C, Husain J, Laferriere N, Rahim Y, Robinson AG, Vandenberg T, Grunfeld E. Krzyzanowska MK, et al. Among authors: dent s. BMJ. 2021 Dec 8;375:e066588. doi: 10.1136/bmj-2021-066588. BMJ. 2021. PMID: 34880055 Free PMC article. Clinical Trial.
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.
Freedman O, Amir E, Dranitsaris G, Napolskikh J, Kumar R, Fralick M, Chia S, Petrella T, Dent S, Tonkin K, Ahmad I, Rayson D, Clemons M. Freedman O, et al. Among authors: dent s. Breast Cancer Res Treat. 2009 Nov;118(2):377-83. doi: 10.1007/s10549-009-0452-8. Epub 2009 Jun 24. Breast Cancer Res Treat. 2009. PMID: 19551499
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI. Wong NS, et al. Among authors: dent s. J Clin Oncol. 2010 Feb 10;28(5):723-30. doi: 10.1200/JCO.2009.24.0143. Epub 2009 Dec 21. J Clin Oncol. 2010. PMID: 20026801 Clinical Trial.
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer.
Grunfeld E, Julian JA, Pond G, Maunsell E, Coyle D, Folkes A, Joy AA, Provencher L, Rayson D, Rheaume DE, Porter GA, Paszat LF, Pritchard KI, Robidoux A, Smith S, Sussman J, Dent S, Sisler J, Wiernikowski J, Levine MN. Grunfeld E, et al. Among authors: dent s. J Clin Oncol. 2011 Dec 20;29(36):4755-62. doi: 10.1200/JCO.2011.36.8373. Epub 2011 Oct 31. J Clin Oncol. 2011. PMID: 22042959 Clinical Trial.
Neoadjuvant chemotherapy in breast cancer: what questions remain?
Sulpher J, Dent R, Dent S. Sulpher J, et al. Among authors: dent s, dent r. Curr Opin Support Palliat Care. 2014 Mar;8(1):59-63. doi: 10.1097/SPC.0000000000000033. Curr Opin Support Palliat Care. 2014. PMID: 24407017 Review.
332 results